SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression - Takeaways - MDSpire

SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression

  • By

  • Jie Yin

  • Jiaxing Liu

  • Meirui He

  • Tang Xiao

  • Wenjuan Xiang

  • Ruxia Sheng

  • Haifang Zhao

  • Xinyue Huang

  • Sheng Xu

  • Yong Zhou

  • Junfeng Liu

  • Ruijuan Heng

  • Xiaoying He

  • Yunxiang Wang

  • Yu Song

  • Pan Qi

  • May 8, 2026

  • 0 min

Share

  • 1

    The acetylation level of XRCC6 is significantly reduced in breast cancer tissues compared to paracancerous tissues.

  • 2

    EP300 is identified as the acetyltransferase, while Sirt7 functions as the specific deacetylase for XRCC6.

  • 3

    Downregulation of XRCC6 acetylation at K591 enhances its interaction with PARP1, increasing DNA damage repair capacity.

  • 4

    Reduced XRCC6 acetylation promotes tumor growth and increases tumor volume in xenograft models.

  • 5

    The study reveals a novel mechanism linking decreased XRCC6 acetylation to breast cancer progression.

Original Source(s)

SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression

  • by Jie Yin, Jiaxing Liu, Meirui He, Tang Xiao, Wenjuan Xiang, Ruxia Sheng, Haifang Zhao, Xinyue Huang, Sheng Xu, Yong Zhou, Junfeng Liu, Ruijuan Heng, Xiaoying He, Yunxiang Wang, Yu Song, Pan Qi

  • May 8, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant